Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Cochrane on Antibiotic Treatment for Cancer Patients

Cochrane; 2017 Jun 3; Beyar-Katz, et al

Publish date:: June 20, 2017

Routinely adding glycopeptides does not improve outcomes in febrile neutropenic patients with cancer, according to a recently updated Cochrane review of 14 trials involving nearly 2,800 individuals. Among the findings:

Mortality did not differ between patients who received anti gram-positive antibiotics and those who did not receive such.
Antibiotic treatment was more frequently modified among patients who did not initially receive specific antibiotics against gram-positive bacteria.
Overall treatment failures were not different.
The addition of specific antibiotics against gram-positive bacteria resulted in more adverse events, mainly rash.

Citation:

Beyar-Katz O, Dickstein Y, Borok S, Vidal L, Leibovici L, Paul M. Empirical antibiotics targeting gram-positive bacteria for the treatment of febrile neutropenic patients with cancer. Cochrane Database of Systematic Reviews. 2017, Issue 6. Art. No.: CD003914. doi:10.1002/14651858.CD003914.pub4.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Patient & Survivor Care

Hemochromatosis variants may confer 10-fold higher risk of liver cancer,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,

Reduced cancer mortality with Medicaid expansion,

Risk factors for severe immune-related AEs identified,

New cancer drugs may have saved more than 1.2 million Americans,